cyrilzakka/clinical-trials huggingface dataset:
Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

The primary objective of this research is to evaluate the effects of non-invasive brain stimulation and computerized cognitive training on executive functioning in individuals with Primary Progressive Aphasia (PPA), mild cognitive impairment (MCI), or dementia. In this study, investigators will use transcranial direct current stimulation (tDCS) to stimulate the left dorsolateral prefrontal cortex (DLPFC). Previous studies have demonstrated that tDCS over the DLPFC led to improvements in attention deficit caused by stroke, Parkinson's Disease, and major depression as well as language deficits caused by neurodegenerative conditions such as primary progressive aphasia or mild cognitive impairment. The investigators seek to expand on this literature by investigating how anodal tDCS paired with and without cognitive training will impact executive functioning in PPA with Frontotemporal Dementia or Alzheimer's Disease pathology and Mild Cognitive Impairment/Alzheimer's Disease (e.g. shifting, updating, monitoring, and manipulation).

In this within-subject cross-over protocol, all participants will receive both, cognitive training and brain stimulation tDCS. Participants will be randomly assigned to begin with either cognitive training and brain stimulation (dual therapy) or just brain stimulation (monotherapy) and will receive the complementary therapy program in the second round of treatment. During each period of therapy, participants will receive 50 treatment sessions over the course of approximately 10 weeks. The computerized cognitive training and brain stimulation will both be preprogrammed to be done at home by the participant.

Eligibility Criteria:
Inclusion Criteria:

* Must be clinically diagnosed with PPA, fronto-temporal dementia (FTD), MCI or mild Alzheimer's disease (AD). Diagnosis will be based on neuropsychological testing, language testing (most commonly the Western Aphasia Battery), MRI, and clinical assessment.
* Must be right-handed.
* Must be proficient in English.
* Must have a minimum high-school education.

Exclusion Criteria:

* Uncorrected visual or hearing impairment by self-report.
* Stroke/other premorbid neurological disorder affecting the brain.
* Any other developmental language-based learning disorder other than PPA.
* Inability to follow directions for baseline tasks.
* Pre-existing psychiatric disorders such as behavioral disturbances, severe depression, and schizophrenia that do not allow them to comply or follow the study schedule and requirements such as repeated evaluation and therapy will be excluded.

Exclusion Criteria for MRI participation:

* Severe claustrophobia.
* Cardiac pacemakers or ferromagnetic implants.
* Pregnant women.
Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response

A randomized, controlled, pilot study, for Patients ≥ 35 years and \< 40 years old with sufficient ovarian reserve parameters (AFC≥ 5), but showed an unexpected poor or suboptimal ovarian response(defined as ≤ 9 retrieved oocytes in previous full-stimulation cycle, but not get live birth after all embryos were used ). In order to get better oocyte number and quality in the new COS cycle, we will compare LH supplementation from beginning with from middle of stimulation in GnRH-a long protocol.


Eligibility Criteria:
Inclusion Criteria:

1.Infertile women, 35≤ Age\< 40 years 2.18\<BMI\<28 Kg/m2 3.5 ≤AFC ≤20 4.Basal serum FSH≤10 IU/L, E2\<70 pg/ml 5.Previous cycle as the first COS cycle,AFC ≥ 5,starting dose of FSH between 150 IU and 300IU with the possibility of adding r-hLH or hMG later in the cycle, number of oocytes retrieved ≤9 (4-9 oocytes retrieval as suboptimal responder and \<4 oocytes retrieval as unexpected poor responder), but not get live birth after all embryos were used.

6.Normal uterus and at least one side of the normal ovary 7.GnRH-a long protocol, using Gonal-F® 300IU and Luveris® 150IU for COS 8.Informed consent form signed 9.Willing to follow the study protocol, and able to complete this study

Exclusion Criteria:

1. Moderate and Severe endometriosis
2. PCOS
3. Previous ovarian surgery history
4. History of recurrent miscarriages (\>2 times of miscarriages)
5. Any major systemic disease that as per Investigator's discretion precludes subject for participation in the study
6. With pregnancy contraindications Alcoholism, drug abuse, drug addiction or patients with uncured sexually transmitted disease
7. According to the judgment of the Investigator, any medical condition or any concomitant surgery/medications that would interfere with evaluation of study medications
8. Simultaneous participation in another clinical study
9. Plan to use other Gn other than Gonal-F® or Luveris® during COS treatment Thyroid gland disorders
Vitamin C on Acute and Chronic Post Mastectomy Pain

This prospective randomized double-blinded controlled study will be conducted to evaluate the effect of perioperative vitamin C on acute and chronic post mastectomy pain after breast cancer surgery

There is cumulative evidence that postoperative pain is closely associated with subsequent persistent pain lasting months. The International Association for the Study of Pain has defined chronic postsurgical pain (CPSP) as a pain that develops after surgical intervention and persists at least 2 months.

Eligibility Criteria:
Inclusion Criteria:

* Female patients aged ≥ 18years, with primary unilateral breast cancer and scheduled for lumpectomy, partial or total mastectomy with or without axillary lymph node dissection or modified radical mastectomy.

Exclusion Criteria:

- (1) Patients with renal stones or renal insufficiency, patients suffering from nausea and vomiting, gastroesophageal reflux or patients with chronic pain state.

(2) Intake of analgesic within 24 hours before surgery. (3) Patients unable to comply with the study protocol for any reason. (4) Contraindications to paravertebral block (PVB) such as allergy to local anesthetics, infection, or coagulopathy.
Radiotherapy - Cerebrovascular Reactivity (RT-CVR Study)

Brain tumours often have low oxygen levels, and that makes them more resistant to radiation therapy. If patients breathe the right mixture of oxygen during treatment, radiation may work better. In this study, patients with brain tumour will undergo a special MRI test while they breathe different mixtures of oxygen and carbon dioxide to find out whether oxygen levels improve in the tumor. Patients will also be asked to repeat this MRI test during the second week of radiation therapy, as well as 3 months, 6 months and 1 year after RT. The MRI test after RT will help us understand how the blood vessels in the normal brain are affected by radiation.


Eligibility Criteria:
Inclusion Criteria:

* Patients with primary gliomas visible on MRI who are planning to receive radiotherapy or
* Patients with brain metastases\>1cm who are planning to receive radiotherapy
* Karnofsky Performance Status \>60
* Age 18 years
* Patients must be willing to visit Toronto Western Hospital for at least one MRI scan prior radiotherapy

Exclusion Criteria:

* Seizures not controlled with medications, or non compliance with prescribed anti-seizure medication
* Prior radiation therapy to the brain
* Pregnancy
* Unwilling or unable to co-operate with breathing maneuvers
* Respiratory or cardiac limitations to breathing at 20 L/min
* Medical contra-indications to limited hypercapnia or hypocapnia (known increased intracerebral pressure, metabolic acidosis or alkalosis)
* Contraindication to MRI (patients weighing\>136 kgs-weight limit for the scanner tables; allergy to MR contrast agent; patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices not compatible with MRI)
* Other medical conditions deemed by the PI or associates to make the patients ineligible for protocol procedures
Chinese Network of Pediatric Antiretroviral Therapy

This is an observational cohort in pediatric HIV patients in China. Children who receive antiretroviral drugs will be recruited in this study. The main objectives are as follows: 1. To establish simpler and smarter pediatric antiretroviral therapy in China including both first-line and second-line regimens. 2. To study the nature, characteristics and mechanisms of immunoreconstitution in HIV-infected children using the data and samples from the pediatric antiretroviral therapy cohort. 3. To establish a basic science and clinical research network based on the pediatric antiretroviral cohort.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of HIV infection
* receiving triple antiretroviral drugs

Exclusion Criteria:

* clinical status not stable
Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

The primary objective of this study is to better understand patients' attitudes and experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This study specifically aims to evaluate attitudes and experiences of people prescribe buprenorphine across five domains with the hope of evaluating a) whether telemedicine has improved their access to and experiences with OBOT; b) the factors that motivate individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis, benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same substances.

Eligibility Criteria:
Inclusion Criteria:

* Participants must be 18 years of age or older.
* Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
* Participants must have a past or present opioid use disorder.
* Participants must currently reside in the state of Massachusetts.
* Participants must be able to comprehend the English language.

Exclusion Criteria:

* Unable to complete an online survey.
* Unable to complete a verification step that ensures bots are not used to complete survey.
* Complete a survey with no variation suggesting they did not read the survey.
Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery

Intravenous lidocaine is efficient for management of post operative pain in abdominal surgery. As previously published in literature the investigators use it during bariatric surgery.

Nevertheless plasmatic concentration of lidocaine is unknown in this population, despite a widespread use.

Investigators propose in this work to bring an objective proof that administration of lidocaine based on a modified body weight is safe.

Intravenous administration concerned the peri operative period. A total of six samples are taken for each patient.

Investigators get approbation of local ethic committee for this work.


Eligibility Criteria:
Inclusion Criteria:

* Adult who perform a bariatric surgery (sleeve, by-pass, mini by-pass) under laparoscopy
* Body mass index \> = 40 kg/m2
* Informed consent signed
* Patient treated with intravenous administration of lidocaine

Exclusion Criteria:

* Contraindication to lidocaine use (allergy, atrioventricular block, seizure, porphyria)
* Concomitant use of beta blocker and others anti arrhythmic drugs
* Cardiac or hepatic insufficiency
* Pregnancy
The Oscillation of Crystalline and Intraocular Lenses

The crystalline lens of the human eye helps to sharpen vision. There can be issues with the support/stability of the lens. This could be seen with the naked eye of an external observer or with the use of a slit lamp.

Certain eye conditions can predispose to issues with lens stability. If patients have stability issues with their natural lens- this would be termed as "phakodonesis". However, in patients who have had prior cataract surgery with implantation of an artificial lens (IOL)- this would be termed as "pseudophakodonesis". Eye conditions such as pseudoexfoliation or Marfan-syndrome can lead to unstable lens support- this can be detected if there are advanced stability issues.

However, small instability in the eye's would not be detected with present descriptive methods. The authors have designed a high-speed camera which is able to detect stability of the lens, especially during eye movements. The high-speed camera can detect variation in the change of light reflex from the lens and calculate the amount of lens instability/oscillation. The results (in normal eyes) of this high-speed camera has already been published in a peer-review journal. It is non-contact and measures lens movement. The test lasts less than 5 minutes.

Further research is required to assess the amount of lens oscillation (wobbling) in different eye populations - patients with previous cataract surgery (an artificial implant is used to replace the lens) or eye conditions (such as pseudoexfoliation, Marfan syndrome). The amount of lens stability has a role in the planning of further intraocular surgery - especially cataract extraction - however, at present, there is no approved quantitative measurement for this.

Participants will be recruited through Anglia Ruskin University (educational establishment), local community groups, and through Southend University Hospital eye clinics (NHS organisation). Participants' data will remain anonymous.


Eligibility Criteria:
Inclusion Criteria:

* \>18 years old
* Able to read and understand the English language

Exclusion Criteria:

* Significant corneal scarring
* Taking medications that cause miosis (pupil constriction)
* Patients with no light perception
* Patients unable to open their eyes e.g. due to significant ptosis
The Effects of Local Infiltration Versus Epidural Following Liver Resection 2

The investigators plan to compare epidurals versus wound catheters for effects on pain relief and recovery following open liver surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing open hepatic resection for benign or malignant conditions.

Exclusion Criteria:

* Patients with contraindication to either epidural or wound catheter techniques.
* Inability to give written, informed consent.
* Jaundice (Bilirubin \> 100 μmol/L)
* Liver resection combined with secondary surgical procedure.
* Age \< 18 years
* Pregnant women
* patients on long term opiates for chronic pain
Vasodilation Effect of Inhalational Anesthetics

Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.


Eligibility Criteria:
Inclusion Criteria:

* Must be undergoing general anesthesia
* Age between 19-45 years

Exclusion Criteria:

* With hypertension
* Existing organic dysfunction
* Allergic to inhalant anesthetics
* Alcohol addictive or narcotic dependent patients
* A history of the use of centrally-acting drugs of any sort, chronic pain and psychiatric diseases records
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS

The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.

A multinational, multicenter, randomized, comparative, open-label, phase 3 study

Primary Objective: To assess the vaccine response rates after the three-dose primary vaccination Secondary Objectives: To measure the antibody titer after the three-dose primary vaccination and to assess the safety of the investigational products

Eligibility Criteria:
Inclusion Criteria:

* Parent/guardian (legally authorized representative) has given voluntary written consent to the subject's participation after being fully informed of the purpose, methods, risks, and benefits of the study.
* Male and female infants reaching at least 7 weeks of age on the day of first dose of investigational product.
* Male and female infants who are identified to be healthy based on physical examination and medical history.

Exclusion Criteria:

* Subjects who have acute febrile illness with tympanic temperature of ≥38.0 ℃ on the day of vaccination.
* Subjects who have moderate or severe acute disease (regardless of fever).
* Subjects who have any history of diphtheria, tetanus, pertussis, or poliomyelitis.
* Subjects who have major congenital defects.
* Subjects who show any evidence of continuous hematologic, hepatic, cardiac, re-nal, or respiratory disease.
* Subjects who have abnormalities in the immune system, or congenital/acquired immune deﬁciency.
* Subjects who received immunosuppressive dose of systemic corticosteroids thera-py within 30 days before the vaccination.
* Subjects who are likely to have adverse side effects on central nervous system be-cause of the subjects' family history of genetic diseases in central nervous system such as progressive neurological problems or epilepsy.
* Subjects who are allergic to the ingredients of the investigational products.
* Subjects who have received immunoglobulins or blood products or plan to get those medications.
* Subjects who have received vaccines other than those allowed in the protocol or plan to get those prohibited vaccines during the study period.
* Subjects who are currently participating or planning to participate in other clinical studies during the study period.
* Other ineligible conditions judged at the discretion of principal investigators or subinvestigators.
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer

Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.

Purpose: to evaluate the efficacy and toxicity of a concomitant treatment using EGFR-TKI and thoracic radiation in elderly patients with esophageal Cancer.

Methods:Patients(\>70 years old) with esophageal Cancer will receive thoracic radiation therapy 54-60 Gy over 30 fractions and concurrent with gefitinib 250mg/day.

Eligibility Criteria:
Inclusion Criteria:

* Histologically documented diagnosis of esophageal Cancer
* Disease must be encompassed in a radiotherapy field.Patients with celiac, perigastric, mediastinal or supraclavicular adenopathy are eligible
* age:70-85 years
* Written informed consent.
* Performance status of 0 to 2
* Neutrophil count \>1.5 x 10 to the 9th power/L and platelets \> 100 x 10 to the 9th power/L.
* Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN) Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN (or less than or equal to 5 times ULN in case of known liver involvement
* Renal: Serum Creatinine less than or equal to 1.5 times upper limit of normal (ULN)

Exclusion Criteria:

* Evidence of tracheoesophageal fistula, or invasion into the trachea or major bronchi.
* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
* Prior systemic chemotherapy or radiation therapy for esophageal cancer
UCB Therapy in Acquired Brain Injury

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with acquired brain injury.

Acquired brain injury (ABI) means brain damage caused by events after birth, rather than as part of a genetic or congenital disorders. Those with ABI suffer from cognitive, physical, or behavioral impairments limiting their activity and participation in society. ABI results from traumatic or non-traumatic brain injury due to internal or external source (e.g. infection, brain tumor, hypoxia). Preclinical studies regarding cell therapy in animal models of ABI showed improvements of neurological dysfunction. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for patients with ABI.

Eligibility Criteria:
Inclusion Criteria:

* Acquired brain injury
* Duration: over 12 months
* Willing to comply with all study procedure

Exclusion Criteria:

* Medical instability including pneumonia or renal function at enrollment
* Uncontrolled persistent epilepsy
* Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
* Not eligible according to the principal investigator